VRCDF (Verici Dx) Accounts Payable & Accrued Expense : $0.67 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Accounts Payable & Accrued Expense?

Verici Dx's quarterly accounts payable & accrued expense declined from Jun. 2023 ($1.03 Mil) to Dec. 2023 ($0.52 Mil) but then increased from Dec. 2023 ($0.52 Mil) to Jun. 2024 ($0.67 Mil).

Verici Dx's annual accounts payable & accrued expense increased from Dec. 2021 ($0.16 Mil) to Dec. 2022 ($0.96 Mil) but then declined from Dec. 2022 ($0.96 Mil) to Dec. 2023 ($0.52 Mil).

Verici Dx Accounts Payable & Accrued Expense Historical Data

The historical data trend for Verici Dx's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Accounts Payable & Accrued Expense Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

0.40

0.16

0.96

0.52

Verici Dx Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial			0.57	0.96	1.03	0.52	0.67

Verici Dx Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Verici Dx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

VRCI:UK 63V:Germany

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines